Transaction · 0001796226-26-000002

Murphy Andrew J

MURPHY ANDREW J, CSO, reported a transaction classified as exercise at REGENERON PHARMACEUTICALS, INC. involving 17000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 17000.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCSO
REGNREGENERON PHARMACEUTICALS, INC.
Trade date
Oct 13, 2026
Filing date
Oct 15, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded17.0k$0.00 per share
Holdings after17.0kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

REGN price since this filing

Daily closing prices, with the filing date and available return windows
REGN · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.3%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001796226-26-000002
Non-Qualified Stock Option (right to buy)
Transaction date
Oct 13, 2026
Filed Oct 15, 2026, 08:02 PM · 2d delay
Shares
17,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
17,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction 10b5-1 Detected
Filing-only score

-16 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Co-Chief Scientific Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.

  2. F2

    Represents volume-weighted average price of sales of 14 shares of Company stock on October 14, 2026 at prices ranging from $759.94 to $759.96. Upon request by the Commission staff, the Company, or a s…

  3. F3

    Represents volume-weighted average price of sales of 74 shares of Company stock on October 14, 2026 at prices ranging from $760.28 to $760.94. Upon request by the Commission staff, the Company, or a s…

  4. F4

    Represents volume-weighted average price of sales of 27 shares of Company stock on October 14, 2026 at prices ranging from $761.01 to $761.68. Upon request by the Commission staff, the Company, or a s…

  5. F5

    Represents volume-weighted average price of sales of 25 shares of Company stock on October 14, 2026 at prices ranging from $763.62 to $763.94. Upon request by the Commission staff, the Company, or a s…

  6. F6

    Represents volume-weighted average price of sales of 219 shares of Company stock on October 14, 2026 at prices ranging from $764.04 to $764.82. Upon request by the Commission staff, the Company, or a…

  7. F7

    Represents volume-weighted average price of sales of 271 shares of Company stock on October 14, 2026 at prices ranging from $765.11 to $765.78. Upon request by the Commission staff, the Company, or a…

  8. F8

    Represents volume-weighted average price of sales of 279 shares of Company stock on October 14, 2026 at prices ranging from $766.00 to $766.95. Upon request by the Commission staff, the Company, or a…

  9. F9

    Represents volume-weighted average price of sales of 192 shares of Company stock on October 14, 2026 at prices ranging from $767.10 to $767.82. Upon request by the Commission staff, the Company, or a…

  10. F10

    Represents volume-weighted average price of sales of 105 shares of Company stock on October 14, 2026 at prices ranging from $768.15 to $768.59. Upon request by the Commission staff, the Company, or a…

  11. F11

    Represents volume-weighted average price of sales of 127 shares of Company stock on October 14, 2026 at prices ranging from $769.15 to $769.93. Upon request by the Commission staff, the Company, or a…

  12. F12

    Represents volume-weighted average price of sales of 283 shares of Company stock on October 14, 2026 at prices ranging from $771.04 to $771.95. Upon request by the Commission staff, the Company, or a…

  13. F13

    Represents volume-weighted average price of sales of 211 shares of Company stock on October 14, 2026 at prices ranging from $772.06 to $772.74. Upon request by the Commission staff, the Company, or a…

  14. F14

    Represents volume-weighted average price of sales of 224 shares of Company stock on October 14, 2026 at prices ranging from $773.14 to $773.84. Upon request by the Commission staff, the Company, or a…

  15. F15

    Represents volume-weighted average price of sales of 121 shares of Company stock on October 14, 2026 at prices ranging from $774.11 to $774.85. Upon request by the Commission staff, the Company, or a…

  16. F16

    Represents volume-weighted average price of sales of 376 shares of Company stock on October 14, 2026 at prices ranging from $775.14 to $775.92. Upon request by the Commission staff, the Company, or a…

  17. F17

    Represents volume-weighted average price of sales of 66 shares of Company stock on October 14, 2026 at prices ranging from $776.00 to $776.98. Upon request by the Commission staff, the Company, or a s…

  18. F18

    Represents volume-weighted average price of sales of 38 shares of Company stock on October 14, 2026 at prices ranging from $777.51 to $777.92. Upon request by the Commission staff, the Company, or a s…

  19. F19

    Represents volume-weighted average price of sales of 454 shares of Company stock on October 14, 2026 at prices ranging from $778.05 to $778.99. Upon request by the Commission staff, the Company, or a…

  20. F20

    Represents volume-weighted average price of sales of 380 shares of Company stock on October 14, 2026 at prices ranging from $779.00 to $779.97. Upon request by the Commission staff, the Company, or a…

  21. F21

    Represents volume-weighted average price of sales of 463 shares of Company stock on October 14, 2026 at prices ranging from $780.06 to $780.89. Upon request by the Commission staff, the Company, or a…

  22. F22

    Represents volume-weighted average price of sales of 50 shares of Company stock on October 14, 2026 at prices ranging from $781.05 to $781.84. Upon request by the Commission staff, the Company, or a s…

  23. F23

    The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Original filing · 0001796226-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

REGN